Waterdrop Inc. reported its unaudited financial results for the first quarter of 2025, highlighting a net profit attributable to ordinary shareholders of RMB108.2 million (US$14.9 million), marking a 34.2% increase year-over-year. The company demonstrated strong liquidity by generating positive operating cash flow during this period. First-year premiums generated through the insurance business reached RMB2,092.4 million (US$288.3 million), reflecting a 19.3% increase compared to the previous year. Additionally, net revenue was RMB753.7 million (US$103.9 million), a 7.0% year-over-year increase. Waterdrop also reported operational advancements, such as the expansion of its medical crowdfunding coverage, with approximately 475 million donors contributing a total of RMB68.8 billion to 3.47 million patients by the end of March 2025. The company improved its risk control framework and expanded its verification platform, now covering 92% of domestic cities. In clinical trials, Waterdrop sustained growth with an 11.5% increase in digital clinical trial solution revenue year-over-year, collaborating with 185 pharmaceutical companies and contract research organizations, while enrolling 822 patients and initiating services for 77 new programs in the first quarter of 2025. No specific future outlook or guidance figures were provided in this release.